Adagene Inc. announced on April 28, 2025, the appointment of Dr. John Maraganore as Executive Advisor. Dr. Maraganore is a recognized biotech luminary, having served as CEO of Alnylam from 2002 to 2021, where he led the company through global approvals and commercialization of four RNA interference therapeutic medicines. His leadership at Alnylam also resulted in the formation of over 20 major pharmaceutical alliances and the creation of over $25 billion in market capitalization.
In his new role, Dr. Maraganore will mentor Adagene's C-suite and provide strategic guidance, leveraging his extensive experience in overcoming complex drug delivery challenges. He noted Adagene's proprietary masking technology is breaking a toxicity barrier by delivering a checkpoint inhibitor selectively and conditionally to tumor cells, highlighting its broad potential for enhanced immunotherapy.
Dr. Maraganore's expertise is particularly relevant to ADG126, Adagene's lead candidate, which aims to deliver anti-CTLA-4 safely to specific T cells while minimizing off-tumor toxicity. His guidance is expected to be instrumental in the company's growth, value creation, and mission to benefit patients by redefining precision immunotherapy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.